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Summary
Objectives: Serum hyaluronan (HA) and chondroitin sulfate (CS) epitopes WF6 and 3B3 (þ) were determined to investigate disease associ-
ation in patients with osteoarthritis (OA), rheumatoid arthritis (RA) and healthy controls.
Methods: Speciﬁc assays for HA and CS epitopes WF6 and 3B3 (þ) were established and applied to a cross-sectional study of serum sam-
ples from patients (96 OA, 57 RA and 50 healthy controls).
Results: Both CS epitopes were increased in serum of many OA and RA patients and average levels were signiﬁcantly above in healthy con-
trols. In contrast serum HA was increased in RA, but only in few OA patients.
Conclusions: CS epitopes WF6 and 3B3 (þ) are raised in serum of patients with both OA and RA and were thus distinct from serum HA. The
results suggest that OA may be detected systemically as well as RA. The range of levels of CS epitopes detected in OA and RA was wide and
correlation with any aspect of disease activity is yet to be determined.
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The diagnosis of osteoarthritis (OA) is generally based upon
clinical and radiographic changes that occur in the later
stages of the disease. There is considerable interest in
identifying better criteria for diagnosis and methods for mon-
itoring disease activity and progression as such methods
would not only enable earlier diagnosis, but would be impor-
tant tools in the development of better treatments1. Mea-
surement of macromolecules released from cartilage into
synovial ﬂuid of OA joints has been investigated to follow
the process of cartilage damage and destruction2. How-
ever, there is limited access to synovial ﬂuid and if charac-
teristic changes were identiﬁed in serum, they would have
much wider application. In the present study we have estab-
lished assays for the investigation of chondroitin sulfate
(CS) epitopes in serum samples of patients with joint dis-
ease. A novel monoclonal antibody (WF6), which recog-
nises a native epitope in CS chains was evaluated
together with a monoclonal antibody 3B3, which recognises
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Received 22 June 2004; revision accepted 8 October 2005.2unsaturated terminal chondroitin 6-sulfate after chondroiti-
nase ABC digestion1,3.
Materials and methods
Assay methods were optimised to investigate these CS
epitopes in normal, OA and RA serum samples. The results
were also compared with measures of serum hyaluronan
(HA), which has been shown to be elevated in serum in pa-
tients with inﬂammatory joint disease such as RA4e7. These
assays were applied to the cross-sectional analysis of serum
from rheumatoid arthritis (RA) and OA patients and healthy
controls in order to evaluate their potential as biomarkers
for joint diseases. OA patients were recruited who were of ei-
ther sex, of age over 40 and were suffering from unilateral
(16%) or bilateral (84%) knee OA and satisﬁed the American
College of Rheumatology (ACR) classiﬁcation criteria for OA
of the knee8 of more than 3 months duration (3.94 2.86
years). The Kellgren and Lawrence X-ray grades were 2%
grade 1, 7% grade 2, 16%grade 3 and 75%grade 4. Patients
took paracetamol 18.9 14.7 tablets (300 mg)/ week. The
median (range) of 100 mm/visual analogue scale (VAS),
Western Ontario and McMaster University Osteoarthritis In-
dex VAS (WOMAC) score and Lequesne’s index are 66
(20e100), 46 (18e96) and 14 (7e21), respectively. Patients
with RA of the knee were diagnosed on the basis of clinical99
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ﬁlled the ACR criteria of RA9. RA patients’ ages were
49.6 12.5 years (range 24e75), and duration of diseases
was 7.9 6.6 years. The disease classiﬁcations10 were 24
in class I, 64 in class II and six in class III, and none were
in class IV. Sixty-six patients (70%) were rheumatoid factor
(RF) positive. Patients were taking chloroquine, methotrex-
ate and sulfasalazine in 71, 52 and two cases, respectively.
No patient took prednisolone. For rheumatological evalua-
tion blood collection and radiographs were completed on
the morning of the same day (between 08:00 and 10:00
a.m. or 3 and 5 h after waking up in the morning). For normal
serum fasting-morning serum samples were collected from
50 healthy blood donors, aged 41e75 years. All subjects
gave their informed consent before participation and the
study received ethical approval from Chiang Mai University.
They were checked to be free from diseases of the joints,
bones, liver, endocrine system, or other chronic disorders
and none were currently taking any medication known to
modify arthritic diseases or inﬂuence joint metabolism.
Sera were stored at 20(C before analysis. A competitive
immunoassay with the monoclonal antibody 3B3 was devel-
oped to analyse human serum for chondroitin 6-sulfate 3B3
(þ) epitope after digestion with chondroitinase ABC. Human
serum samples were also assayed by a competitive immu-
noassay with monoclonal antibody WF6, which recognises
native epitopes in CS chains without chondroitinase ABC
digestion. Serum HA was also determined using an
enzyme-linked immunosorbent assay (ELISA) based assay
using biotinylated HA binding proteins.
Results and discussion
The analysis of HA in serum of patients with joint dis-
eases has shown increased levels particularly in those
with RA4e6. It has also been reported that in patients with
knee OA a higher value at onset was predictive of a more
rapid progression7. In this study the results with a newly de-
veloped assay were comparable with previous results
amongst clinically deﬁned patient groups showing many
RA patients (23/57) and also a few OA patients (17/96)
with high serum HA.
It is interesting to compare the results for serum HA with
the results for the CS epitopes, 3B3 (þ) and WF6. The 3B3
(þ) epitope may provide a measure of the mobilisation of
tissue proteoglycans containing chondroitin 6-sulfate. This
might be expected to parallel the release of HA. The results
(Fig. 1) showed that indeed many RA samples contained
very high levels of 3B3 (þ) epitope, however, there was
no signiﬁcant correlation between serum HA and serum
3B3 (þ) and they varied independently of each other. The
OA sera also contained levels of 3B3 (þ) epitope signiﬁ-
cantly higher than normal. Clearly, tissue mobilisation of
HA, which might be caused by inﬂammation, is driven by
different processes from those that raise serum 3B3 (þ).
The native CS epitope detected by monoclonal antibody
WF6 was also raised above normal in RA and OA serum.
This might imply that 3B3 (þ) and WF6 detect the same
components in serum, however, analysis of the results
showed that they also varied independently of each other.
They are thus detecting unlinked features of the CS struc-
tures in serum. As there are many different CS proteogly-
cans in the body, the epitopes may be part of different
proteoglycans from different tissue sources. The high levels
of WF6 epitope in RA and OA may reﬂect an increase in
synthesis in joints or other tissues, or its preferential release
into serum. The investigation of another CS epitope (846)has been suggested to reﬂect an increase in synthesis
and has been reported to be highest in serum of early RA
patients with slow disease progression11. An increase in
WF6 epitope may also reﬂect an anabolic response and it
may be helpful in diagnosis or prognosis.
The 3B3 epitope is a 6-sulfated terminal disaccharide on
CS1. The antibody reacts with both native terminal disac-
charides (denoted 3B3 ()) and after chondroitinase diges-
tion with reduced terminal disaccharides (denoted 3B3
(þ))1,3. However, the 3B3 () epitope is uncommon in native
CS chains12 and the detectible epitope was increased after
digestion by 20e100 fold in serum samples. The 3B3 (þ)
assay developed in this study with monoclonal antibody
(mAb) thus recognises unsaturated terminal 6-sulfated di-
saccharide structures remaining attached to protein after
chondroitinase ABC digestion. As 3B3 is an immunoglobulin
M (IgM), it is likely to be more reactive to polyvalent antigens
and proteoglycan fragments with several chains and several
epitopes may be more competitive in the assay13. The assay
of 3B3 () in serum has been reported to show levels lower
than normal in early RA14. The serum results with 3B3 (þ)
and WF6 may, therefore, reﬂect systemic changes that ac-
company joint disease, or they may be selectively contribut-
ed to by joint components if these are particularly reactive in
the assays and enter the circulationwithout efﬁcient removal.
Fig. 1. Serum concentration of HA and CS epitopes WF6 and 3B3
(þ) in OA, RA and healthy controls (normal). Boxes represent me-
dian and the interquartile range, between 5th and 95th quartile with
error bars. Statistically signiﬁcant difference (P< 0.001 shown with
double asterisks) relative to the median of the normal serum.
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be present in serum and to be polyvalent, the detection with
3B3 (þ) may selectively provide a measure of catabolism in
cartilaginous tissues.
The circulating level of CS epitopes is a balance of sev-
eral factors; the release from tissues, the uptake within
the lymphatics and their removal from serum by the liver
once they have entered the circulation. Serum detection
of WF6 and 3B3 (þ) may, therefore, be inﬂuenced by other
factors that compromise liver uptake or kidney excretion of
CS proteoglycan metabolites and care was taken in this
study to exclude any patients with other non-joint related
pathology from the study.
The determination of the CS epitopes 3B3 (þ) and WF6
in serum show increases in groups of both OA and RA pa-
tients and they may therefore prove useful in the differential
diagnosis and monitoring of joint diseases. Whilst mean se-
rum concentrations of 3B3 (þ) and WF6 epitopes were
raised in these disease groups, the distribution of levels
found was broad and it is interesting that some patients
were in the normal range. There were no obvious clinical
criteria that distinguished those with high values from those
with low values in this cross-sectional study and whether it
relates to disease activity or progression will need to be
evaluated in a more detailed longitudinal study.
Acknowledgements
The Thailand Research Fund (Basic Research Grant to
PK), The Royal Golden Jubilee Ph.D. Program, Grant No.
PHD/0121/2544 (to PP) and the National Research Council
of Thailand (Research Programme of Drug, Chemical, Med-
ical Material and Equipment) jointly funded this work.
References
1. Caterson B, Mahmoodian F, Sorrell JM, Hardingham T,
Bayliss MT, Carney SL, et al. Modulation of native
chondroitin sulphate structure in tissue development
and in disease. J Cell Sci 1990;97:411e7.
2. Lohmander S. Markers of cartilage metabolism in ar-
throsis. Acta Orthop Scand 1991;62:623e32.
3. Caterson B, HughesCE, JohnstoneB,Mort JS. Immuno-
logical markers of cartilage proteoglycan metabolism
in animal and human osteoarthritis. In: Kuettner K,
Schleyerback R, Peyron J, Hascall V, Eds. ArticularCartilage and Osteoarthritis. New York: Raven Press
1992:415e426.
4. Paimela L, Heiskanen A, Kurki P, Helve T, Leirisalo-
Repo M. Serum hyaluronate levels as a predictor of
radiologic progression in early rheumatoid arthritis.
Arthritis Rheum 1991;34:815e21.
5. Laurent TC, Fraser JRE, Laurent UBG, Engstrom-
Laurent AE. Hyaluronan in inﬂammatory joint disease.
Acta Orthop Scand 1995;66:116e20.
6. Fex E, Eberhardt K, Saxne T. Tissue derived macromo-
lecules and markers of inﬂammation in serum in early
rheumatoid arthritis: relationship to development of
joint destruction in hands and feet. Br J Rheumatol
1997;36:1161e5.
7. Sharif M, George E, Shepstone L, Knudson W,
Thonar EJ, Cushnaghan J, et al. Serum hyaluronic
acid as a predictor of disease progression in osteoar-
thritis of the knee. Arthritis Rheum 1995;38:760e7.
8. Altman R, Asch E, Bloch D, et al. Development of crite-
ria for the classiﬁcation and reporting of osteoarthritis.
Arthritis Rheum 1986;29:1039e49.
9. Arnett FC, Edworthy SM, Bloch DA, et al. The American
Rheumatism Association 1987 revised criteria for the
classiﬁcation of rheumatoid arthritis. Arthritis Rheum
1988;31:315e24.
10. Hochberg MC, Chan RW, Dwosh I, et al. The American
College of Rheumatology 1991 revised criteria for the
classiﬁcation of global functional status in rheumatoid
arthritis. Arthritis Rheum 1992;35:498e502.
11. Hardingham TE. Immunochemical methods in cartilage
research. In: Maroudas A, Keuttner K, Eds. Methods in
Cartilage Research. London: Academic Press 1991:
155e164.
12. Mansson B, Carey D, Alini M, Ionescu M,
Rosenberg LC, Poole AR, et al. Cartilage and bone
metabolism in rheumatoid arthritis. Differences be-
tween rapid and slow progression of disease identiﬁed
by serum markers of cartilage metabolism. J Clin
Invest 1995;95:1071e7.
13. Plaas AH, West LA, Wong-Palms S, Nelson FR. Gly-
cosaminoglycan sulfation in human osteoarthritis. Dis-
ease related alterations in the non-reducing termini of
chondroitin and dermatan sulphate. J Biol Chem 1998;
273:12642e9.
14. Middleton J, White S, Parry E, Jackson J, Dixey J,
Ashton B. Changes in serum chondroitin sulphate epit-
opes 3B3 and 7D4 in early rheumatoid arthritis. Rheu-
matology 1999;38:837e40.
